Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock Award Plans (Tables)

Stock Award Plans (Tables)

3 Months Ended

Mar. 31, 2013

Schedule of stock-based compensation expense related to all of the entity's stock-based awards

Total stock-based compensation expense related to all of our stock-based awards that we recognized was as follows (in thousands):

	Three Months Ended
	March 31,
	2013		2012
Research and development	$	1,023	$	1,712
General and administrative	770		1,386
Total stock-based compensation expense	$	1,793	$	3,098

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans

	Equity Incentive Plans
	Three Months Ended
	March 31,
	2013		2012
Risk-free interest rate	0.8	%	0.9	%
Expected term (in years)	5.5		5.5
Dividend yield	0.0	%	0.0	%
Expected volatility	73.4	%	81.7	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan

	Employee Stock Purchase Plan
	Three Months Ended
	March 31,
	2013		2012
Risk-free interest rate	0.2	%	0.1	%
Expected term (in years)	1.4		0.5
Dividend yield	0.0	%	0.0	%
Expected volatility	58.0	%	49.7	%

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details